Commit Biologics, the Copenhagen-based biotech company developing complement-powered immune engagers, has appointed serial entrepreneur Thomas L. F. Montgomery Andresen as its new CEO. Andresen takes over from Mikkel Wandahl Pedersen, who moves to Chief Scientific Officer, and starts March 16.

The timing isn't accidental. Commit is sitting on preclinical data it calls "outstanding," including non-human primate results showing deep B-cell depletion without the cytokine release that plagues most immunotherapies. The company plans to nominate its first two clinical development candidates later this year. For that kind of transition, you don't just need a scientist running the show. You need someone who's built companies from the lab into the clinic before.

Andresen has done exactly that. Multiple times.

Andresen's background sits at the crossover of therapeutic innovation and bioengineering. He's spent more than 20 years building biotech ventures, converting scientific breakthroughs into commercial technologies, and raising institutional capital to fund the transition. His most recent role was at T-Cypher Bio. Before that, he built and scaled multiple companies across Europe and the US.

"Commit is redefining immunotherapy by activating the complement system, one of the immune system's most potent, yet untapped weapons," Andresen said in a statement. He described complement-powered immune engagers as "the next breakthrough modality" following checkpoint inhibitors, CAR-T cells, and T-cell engagers.

That's a big claim. But the immune complement system has been largely ignored by drug developers, not because it lacks potential, but because nobody has figured out how to activate it safely and selectively. If Commit's non-human primate data holds up in humans, the company is sitting on something genuinely novel.

Commit raised a EUR 21.5 million seed round backed by Novo Holdings, the investment arm of the Novo Nordisk Foundation and one of the largest life science investors globally. Bioqube Ventures and Korys also participated.

Having Novo Holdings as a seed investor is significant for a reason beyond the money. Novo's ecosystem includes deep connections to clinical development infrastructure, regulatory expertise, and a portfolio of complementary companies. For a biotech heading into the clinic for the first time, those connections can shave years off the development timeline.

The seed round itself was large by European biotech standards. EUR 21.5 million gives Commit enough runway to fund preclinical optimization, manufacturing scale-up, and early clinical work without needing to raise again before it has human data. That's a luxury most early-stage biotechs don't have.

The complement system is part of your innate immune defense. It's a cascade of proteins that can mark cells for destruction, punch holes in their membranes, or recruit other immune cells to finish the job. Unlike T-cells and antibodies, which need to be trained or engineered, the complement system is already there, waiting.

The problem has always been control. Activate the complement system indiscriminately and you get inflammation, tissue damage, and cytokine storms. Commit's approach uses engineered molecules to direct complement activation specifically at target cells, like B-cells in autoimmune disease, while leaving healthy tissue alone.

The non-human primate data showed deep depletion of B-cells without triggering cytokine release. If you've followed the CAR-T field, you know that cytokine release syndrome is one of the biggest safety concerns in immunotherapy. A modality that achieves comparable efficacy without that risk would be meaningful.

Copenhagen has quietly become one of Europe's most productive biotech hubs. The Medicon Valley cluster, spanning Denmark and southern Sweden, is home to companies like Novo Nordisk, Lundbeck, Genmab, and Zealand Pharma. The concentration of pharmaceutical expertise, clinical infrastructure, and academic research creates an environment where companies like Commit can access talent and resources that would be difficult to assemble anywhere else.

Andresen's appointment signals that Commit is serious about the clinical transition. Companies don't bring in serial founders with two decades of company-building experience to run preclinical research. They bring them in to take a platform from promising data to an actual drug. The next 18 months will determine whether Commit's complement thesis is as breakthrough as its new CEO believes.

Pedersen, who founded the company and built the platform as CEO, isn't leaving. His shift to CSO means the science stays in the hands of the person who understands it best, while the business execution moves to someone built for that specific phase. It's a transition that sounds obvious but rarely happens this cleanly in early-stage biotech.